Article Sidebar

PDF
Date Published: 22/08/2022
Abstract Views: 216
Views PDF: 202
DOI: https://doi.org/10.51298/vmj.v517i1.3200
Issue
Vol. 517 No. 1 (2022)
Section
Các bài báo
How to Cite
Thị Dịu, P. ., & Thanh Đức, L. . (2022). THE EFFICACY OF PACLITAXEL REGIMEN FOR RECURRENT OR METASTATIC IN BREAST CANCER. Vietnam Medical Journal, 517(1). https://doi.org/10.51298/vmj.v517i1.3200

THE EFFICACY OF PACLITAXEL REGIMEN FOR RECURRENT OR METASTATIC IN BREAST CANCER

Phạm Thị Dịu1,, Lê Thanh Đức2
1 Haiduong Medical Technical University
2 Vietnam National Cancer Hospital

Main Article Content

Abstract

Objectives: Describe the clinical and paraclinical characteristics of metastatic breast cancer patients and evaluate the efficacy of paclitaxel regimen for recurrent or metastatic in breast cancer. Patients and methods: Retrospective, descriptive study on 39 patients with recurrent or metastatic of breast cancer, were treated with paclitaxel chemotherapy regimen at National Cancer Hospital. Results: The mean age was 56,8 ±9,8. In 32 patients of recurrent, mean time to first recurrence was 39 months. The overall response rate (ORR) of the regimen was 33,3 %. The complete response rate was 5,1%, the partial response rate was 28,2%, 46,2% of the patients were stable. ORR in first-line therapy was better than that in the second-line of treatment (ORR: 40,7% vs 25%; p=0,031). The median progression-free survival was 5,6 ± 0,3 months. The common toxicity was neutropenia (33,5%), anemia (38,6%), 10,3% for thrombocytopenia, hair loss (38,5%), and 51,3% for neurotoxicity. Conclusion: Paclitaxel regimen chemotherapy is effective in high response rates and progression-free survival for patients with recurrent or metastatic of breast cancer. It is well tolerated by patients. Therefore, it can be widely applied in clinical practice.

Article Details

Keywords

metastatic breast cancer, paclitaxel, progression-free survival

References

1. Sung H., Ferlay J., Siegel R.L. và cộng sự. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3), 209–249.
2. van Maaren M.C., de Munck L., Strobbe L.J.A. và cộng sự. (2019). Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer, 144(2), 263–272.
3. Mátrai Z. và Rényi Vámos F. (2014). [Surgical possibilities in the treatment of advanced and locally recurrent breast cancers]. Orv Hetil, 155(37), 1461–1468.
4. Conlin A.K. và Seidman A.D. (2007). Taxanes in breast cancer: an update. Curr Oncol Rep, 9(1), 22–30.
5. Jones S.E., Erban J., Overmoyer B. và cộng sự. (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol, 23(24), 5542–5551.
6. Sledge G.W., Neuberg D., Bernardo P. và cộng sự. (2003). Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol Off J Am Soc Clin Oncol, 21(4), 588–592.
7. Bishop J.F., Dewar J., Toner G.C. và cộng sự. (1999). Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol, 17(8), 2355–2364.
8. Clark G.M., Sledge G.W., Osborne C.K. và cộng sự. (1987). Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol Off J Am Soc Clin Oncol, 5(1), 55–61.